New clinical data show omilancor reduced a molecular signature associated with biologic refractoriness by more than 55% in ...
The placebo rate was 33% versus 70% anticipated, limiting statistical power; larger studies may further assess protection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results